Likarda

Likarda is developing innovative cell and gene therapy delivery methods to treat various diseases. Similar to how drugs can be delivered through various forms i.e tablets, capsules or slow-release formulations, each with their own benefits and applications, Likarda has patented formulation technologies for all kinds of cell therapies. The formulation technology is part of Likarda’s versatile microencapsulation platform, which is a novel, non-cytotoxic method to produce hydrogel microspheres to encompass cell therapies. The platform can use any cross linkable hydrogel providing a plethora of customizable options to ensure cell therapies get to, and stay, where they can be most effective.

Jobs: